多发性硬化症的疾病生物标志物:当前血清神经丝轻链的观点。

IF 2.3 Q3 CLINICAL NEUROLOGY
Neurodegenerative disease management Pub Date : 2021-08-01 Epub Date: 2021-07-01 DOI:10.2217/nmt-2020-0058
Dejan Jakimovski, Michael G Dwyer, Niels Bergsland, Bianca Weinstock-Guttman, Robert Zivadinov
{"title":"多发性硬化症的疾病生物标志物:当前血清神经丝轻链的观点。","authors":"Dejan Jakimovski,&nbsp;Michael G Dwyer,&nbsp;Niels Bergsland,&nbsp;Bianca Weinstock-Guttman,&nbsp;Robert Zivadinov","doi":"10.2217/nmt-2020-0058","DOIUrl":null,"url":null,"abstract":"<p><p>The continuous neuroinflammatory and neurodegenerative pathology in multiple sclerosis (MS) results in irreversible accumulation of physical and cognitive disability. Reliable early detection of MS disease processes can aid in the diagnosis, monitoring and treatment management of MS patients. Recent assay technological advancements now allow reliable quantification of serum-based neurofilament light chain (sNfL) levels, which provide temporal information regarding the degree of neuroaxonal damage. The relationship and predictive value of sNfL with clinical and cognitive outcomes, other paraclinical measures and treatment response is reviewed. sNfL measurement is an emerging, noninvasive and disease-responsive MS biomarker that is currently utilized in research and clinical trial settings. Understanding sNfL confounders and further assay standardization will allow clinical implementation of this biomarker.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"11 4","pages":"329-340"},"PeriodicalIF":2.3000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives.\",\"authors\":\"Dejan Jakimovski,&nbsp;Michael G Dwyer,&nbsp;Niels Bergsland,&nbsp;Bianca Weinstock-Guttman,&nbsp;Robert Zivadinov\",\"doi\":\"10.2217/nmt-2020-0058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The continuous neuroinflammatory and neurodegenerative pathology in multiple sclerosis (MS) results in irreversible accumulation of physical and cognitive disability. Reliable early detection of MS disease processes can aid in the diagnosis, monitoring and treatment management of MS patients. Recent assay technological advancements now allow reliable quantification of serum-based neurofilament light chain (sNfL) levels, which provide temporal information regarding the degree of neuroaxonal damage. The relationship and predictive value of sNfL with clinical and cognitive outcomes, other paraclinical measures and treatment response is reviewed. sNfL measurement is an emerging, noninvasive and disease-responsive MS biomarker that is currently utilized in research and clinical trial settings. Understanding sNfL confounders and further assay standardization will allow clinical implementation of this biomarker.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\"11 4\",\"pages\":\"329-340\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2021-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2020-0058\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/7/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2020-0058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 4

摘要

多发性硬化症(MS)持续的神经炎症和神经退行性病理导致身体和认知障碍的不可逆积累。可靠的MS疾病过程早期检测有助于MS患者的诊断、监测和治疗管理。最近的分析技术进步现在允许可靠的定量血清为基础的神经丝轻链(sNfL)水平,它提供了关于神经轴突损伤程度的时间信息。本文综述了sNfL与临床和认知结局、其他临床旁措施和治疗反应的关系和预测价值。sNfL测量是一种新兴的、无创的和疾病反应性的MS生物标志物,目前用于研究和临床试验环境。了解sNfL混杂因素和进一步的检测标准化将允许该生物标志物的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives.

The continuous neuroinflammatory and neurodegenerative pathology in multiple sclerosis (MS) results in irreversible accumulation of physical and cognitive disability. Reliable early detection of MS disease processes can aid in the diagnosis, monitoring and treatment management of MS patients. Recent assay technological advancements now allow reliable quantification of serum-based neurofilament light chain (sNfL) levels, which provide temporal information regarding the degree of neuroaxonal damage. The relationship and predictive value of sNfL with clinical and cognitive outcomes, other paraclinical measures and treatment response is reviewed. sNfL measurement is an emerging, noninvasive and disease-responsive MS biomarker that is currently utilized in research and clinical trial settings. Understanding sNfL confounders and further assay standardization will allow clinical implementation of this biomarker.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
35
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信